Chapters

Transcript

Video

What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy?

What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Vincent Woo, MD, FRCPC

Vincent Woo, MD, FRCPC

Endocrinology and Metabolism

Endocrinology and Metabolism
University of Manitoba
Principal Investigator
Diabetes Research Group
John Buhler Research Centre
Winnipeg, Manitoba, Canada